IJCRT.ORG

ISSN: 2320-2882



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Sustained Ophthalmic Drug Delivery of In-Situ Gel of Ofloxacin

Dalsingh, Swati Saxena*, Sarang Kumar Jain

Rajiv Gandhi College of pharmacy, Bhopal

Abstract:

Ophthalmic drug delivery is one of the most widely used drug delivery systems for the delivery drug to eye section. In situ gels are a type of formulations in which drug is ingested in solution form and while coming in contact with body fluids or temperature, it gets converted to gel form in order to produce a sustained release formulation. The objective of present work is to develop in situ gel of ofloxacin which is an antibiotic for bacterial infections.it is a type of broad spectrum antibiotic. It has a low molecular weight of 361.368gm/mol. It is one of the most suitable candidates for ophthalmic drug delivery. Ofloxacin is an antibiotic that is used to treat bacterial infections; it stops the multiplication of bacteria by inhibiting the reproduction and repair of their genetic material (DNA). Marketed eye drop solution is cleared very rapidly from the corneal region whereas, in-situ gelling systems, it was observed that clearing time is slow and retention of drug is for longer period at the corneal surface for a longer duration Ofloxacin can be targeted in treatment of the bacterial infection and also reduce dosing frequency, increase bioavailability of Ofloxacin that will result in better patient compliance with minimum side effects.

Keywords: Ophthalmic Drug delivery, In situ gel, sol form, gelling state, Ofloxacin

Introduction:

Ophthalmic drug delivery system is one of the most widely used areas for around several years. It is one of the most widely researched areas in the field of medicines. The young generation of scientist has a very keen interest in this ophthalmic field nowadays. The main reason of continuous strong interest of scientists in this drug delivery system is the problem of a low bioavailability of drug after the application to the eyeball. [1] Gelling capacity and gelling temperature both play an important role in formulation of *In-situ* gel. Both the parameters are determined to check the ability of the formulation to form a gel due to interaction with different environmental conditions like temperature, pH, humidity etc.

The formulation should undergo rapid conversion between sol to gel transition at the site of application due to change in pH and temperature by maintaining its integrity without erosion or dissolution. On experimentation it was found that as the concentration of polymers increases, the integrity of formed gel also increases. As a result it remains in gel form for a prolonged period of time ensuring proper drug release from the formed gel.

The viscosities of all the formulations at cold temperature and at 37°C were in the range between 980 to 1839 and 6032 to 8907 centipoises respectively. [2] These in situ solutions are liquid at room temperature but undergo gelation when it comes in contact with body fluids or change in pH. [3] The goal of any drug delivery system is to provide adequate quantity of drug at the targeted site of action to perform its required pharmacological response. That Spatial placement relates to targeting a drug to a specific organ or tissue, while temporal delivery refers to controlling the rate of drug delivery to the target tissue. A sustained release drug delivery system can be a major advancement in curing ophthalmic diseases. Mostly sustained-release forms are designed in such a manner so that a small amount of dose can provide required pharmacological response for long period of time usually 8 to 12hrs.[4] The formulations of in situ gels possibly possess characteristics of a pseudo plastic behavior. The developed formulations were therapeutically efficacious, stable, non -irritant and provide sustained release of the drug up to eight hours. [5]

Materials and methods:

Drug ofloxacin was obtained as a gift sample from Cipla, Indore. Sodium alginate polymer, Carbopol 934, Hydroxy propyl methyl cellulose, Chitosan was obtained from Oxford Laboratory Mumbai. Glacial Acetic Acid was obtained from Sara Fine Chemical, Vadodara. Calcium chloride ware obtained from Qualigens fine IJCRI chemicals.

Preformulation Parameters

Organoleptic evaluation

Colour / Odour

A small quantity of drug was taken on butter paper and it was analysed visually for analysing colour and odour.

Melting Point

Melting point is defined as temperature at which drug gets converted from solid to liquefied form. It is determined mainly by two methods: Capillary tube Method (Fusion Method) and through Melting point apparatus (Navyug, India). The melting point was determined by fusion method. A capillary tube was sealed at one end, and then filled with small amount of drug (Ofloxacin) sample. The capillary tube was inserted into melting point apparatus along with thermometer till drug sample gets melted and temperature was recorded.

Solubility Analysis

Solubility is the property of a solid, liquid or gaseous chemical substance called solute to dissolve in a solid, liquid or gaseous solvent. The solubility of a substance fundamentally depends on the physical and chemical properties of the solute and solvent as well as on temperature, pressure and presence of other chemical (including charge to the pH) of the solution.

Table 1: Solubility Profile according to BP

S.NO.	Description term	Part of solvent required for part of
		solute
1.	Very Soluble	Less than 1ml
2.	Freely Soluble	From 1ml to 10ml
3.	Soluble	From 10ml to 30ml
4.	Sparingly Soluble	From 30ml to 100ml
5.	Slightly Soluble	From 100ml to 1000ml
6.	Very Slightly Soluble	From 1000 to 10000
7.	Practically in soluble	From 10000 or more

Procedure:

Take a small amount of drug in a test tube. Then check its solubility in different solvents like distilled water, 0.1N HCl, 0.1N NaOH, ethanol, methanol, phosphate buffer pH 7.2 & 6.8.

Determination of Absorption Maxima of Ofloxacin

Preparation of Phosphate buffer pH 7.2:

34 gm of potassium dihydrogen phosphate were dissolved in 1000ml to produce phosphate buffer of pH 7.4.

Spectrophotometric estimation of ofloxacin

Ofloxacin was analysed quantitatively by UV spectrophotometer (Systronics 2202) in Phosphate buffer pH 7.2. Standard calibration curve was plotted between concentration and absorbance.

Procedure for preparation of standard curve of ofloxacin in phosphate buffer pH 7.2

Weigh 100 mg of drug and dissolve in 100ml of phosphate buffer solution pH 7.2. Pipette out 1ml of stock solution and dilute to 100ml of phosphate buffer solution (Sub stock solution). Then pipette out 0.1ml, 0.2ml, 0.3ml, 0.4ml, 0.5ml from sub stock solution and dilute up to 10ml to prepare 1 µg/ml, 2 µg/ml, 3 µg/ml, 4 μg/ml and 5 μg/ml solution. Then absorbance is recorded using UV spectrophotometer at λ max 286nm.

Determination of Drug Excipients Incompatibility by FT-IR Spectroscopy

Infra red spectra were recorded by mixing powdered drug with dry powder potassium bromide. FT-IR spectra of the selected formulations were taken and compared with the spectrum of pure drug. The characteristic peaks of drug were obtained by scanning in the range of 400-4000 cm-1 by using the spectrometer (Bruker-α-T, Germany). FT-IR is a technique used to determine the chemical interaction between drug and polymers.

Formulation Batch In situ gel:

Table 2 Formulation Batch In situ gel

Formulation	Drug	Carbopol	HPMC (%)	Chitosan	Sodium
batch		934 (%)		(%)	alginate (%)
F1	0.3	1	-	-	-
F2	0.3	-	2	-	-
F3	0.3	-	-	0.25	-
F4	0.3	-	-	-	8

Formulation of in situ gel

Carbopol 934 - The weighed quantities of polymers were kept for swelling overnight in distilled water and dissolved (heated, if necessary) using a magnetic stirrer. Aqueous solution of Ofloxacin was added in to the polymeric solution with continuous agitation for 20 min. Benzalkonium chloride was added to the resulting solution. The pH of the formulation was adjusted to 7.2 using 0.1 N NaoH/0.1 N HCl. Dispersion was allowed to hydrate for 60 min. Keep the gel for 24 hrs at room temperature.

HPMC (E15) - The weighed quantities of polymers were kept for swelling overnight in distilled water and dissolved (heated, if necessary) using a magnetic stirrer. Aqueous solution of Ofloxacin was added in to the polymeric solution with continuous agitation for 20 min. Benzalkonium chloride was added to the resulting solution. The pH of the formulation was adjusted to 7.2 using 0.1 N NaoH/0.1 N HCl. Dispersion was allowed to hydrate for 60 min. Keep the gel for 24 hrs at room temperature.

Chitosan - The weighed quantities of polymers were kept for swelling overnight in mix of 0.25% glacial acetic acid and distilled water and dissolved (heated, if necessary) using a magnetic stirrer. Aqueous solution of Ofloxacin was added in to the polymeric solution with continuous agitation for 20 min. Benzalkonium chloride was added to the resulting solution. The pH of the formulation was adjusted to 7.2 using 0.1 N NaoH/0.1 N HCl. Dispersion was allowed to hydrate for 60 min. Keep the gel for 24 hrs at room temperature.

Sodium Alginate - The weighed quantities of polymers were kept for swelling overnight in distilled water and dissolved (heated, if necessary) using a magnetic stirrer. Aqueous solution of Ofloxacin was added in to the polymeric solution with continuous agitation for 20 min. Benzalkonium chloride was added to the resulting solution. The pH of the formulation was adjusted to 7.2 using 0.1 N NaoH/0.1 N HCl. Dispersion was allowed to hydrate for 60 min. Keep the gel for 24 hrs at room temperature.

Evaluation Parameter

Clarity Test:

Clarity test was observed by visual inspection under a good light, viewed against a black and white background, with the contents set in motion with a swirling action. Also it was observed for formation of turbidity or any unwanted particles dispersed in the solution [6].

Determination of pH:

pH of each formulation was determined immediately after preparation by using digital pH meter (EI Instrument, Parwanoo H.P.) which was previously calibrated by pH 4 and pH 7 standard buffers.[7]

Gelling Capacity:

The gelling capacity of the prepared formulation was determined by placing a drop of the formulation in a beaker containing 50 ml of freshly prepared concentrated calcium chloride solution and was visually observed for gelling time. [8].

Measurement of Gelation Temperature:

About 10 ml of the formulation was transferred to a 50 ml beaker with a magnetic bead and placed on a magnetic stirrer (Jyoti Scientific Industries, Gwalior) with thermostatically controlled heater. The temperature of the stirrer was increased in increments of 1°C and the temperature of the formulation was recorded using a thermometer. The rotation of bead gradually slowed down as the viscosity increased. The temperature at which the magnetic bead stopped rotating was taken as gelation temperature [9].

Viscosity Measurement:

The viscosity was measured using a Brookfield viscometer (Brookfield engineering limited) and the angular velocity increased gradually from 2 to 50 rpm. The studies were performed using spindle no. 96 for gels at physiological temperature (37°C) and for sols at normal room temperature (28°C) [10].

In-Vitro Release Studies:

The in-vitro drug release was studied by using a USP rotating paddle apparatus (Electro Lab, TDT 08L). Phosphate buffer 7.2 maintained at 37oC was used as the medium. The paddle speed was set to 50 rpm. 3ml of the formulation was placed in a dialysis tube with cellophane membrane covered cells and it was placed such that it just touches the diffusion medium. The drug samples were withdrawn at the interval of one hour for a period of ten hours from the medium and were analyzed by U.V spectrophotometer at their respective wavelength using Phosphate buffer pH 7.2 as blank. The cumulative percentage drug release was evaluated.

Results and discussion:

Organolaptic evaluation

The drug was found to be creamish amorphous powder. The melting point of drug was found to be $250^{\circ}\text{C} - 257^{\circ}\text{C}$. The drug does not have any obnoxious odour. Ofloxacin is soluble in phosphate buffer pH 7.2, it is slightly soluble in water, ethanol, and methanol. It is very slightly soluble in 0.1N HCl. It is sparingly soluble in 0.1 N NaOH.

Determination of Absorption Maxima of ofloxacin

Calibration curve of ofloxacin in phosphate buffer pH 7.2:




Fig 1: Calibration curve of ofloxacin


Table 3: Concentration and absorbance data for calibration curve of ofloxacin


1	S.	N	0	Concentration (μg/ml)	Absorbance (at 286nm)
-	1		-	0	0
	2			1	0.096
	3			2	0.167
	4			3	0.235
	5			4	0.296
١Ē	6			5	0.379

FT-IR studies

Drug-excipients compatibility study was performed by FTIR technique. The IR spectra of the solution were taken, which indicate no interaction between Ofloxacin HCl and polymers [12,13]. FT-IR spectrum of drug and polymer mixture shows characteristic peaks at 3035cm_1 indicates the presence of carboxylic group, 1616cm_1 exhibits alkenes, 1450cm_1 indicates the presence of aromatic ring, 1355cm_1 exhibits carboxylic acids, 1288cm_1 indicates alkyl halides, 1239cm_1 indicate esester, 1196cm_1 indicates alkyl halide, and 1135cm_1 indicates amine oxide. From the spectral study it was observed that there was no significant change in the peaks of drug polymer mixture. Hence, no specific interaction was observed between the drug and the polymers used in the formulations

SAGAR INSTITUTE OF RESEARCH TECHNOLOGY-PHARMACY-BHOPAL





The formulations (F1–F4) were prepared by using various concentrations of sodium alginate along with HPMC in different ratios. All the formulations prepared were clear without any turbidity and suspended particles or impurities.

Determination of pH:

The pH of in situ gel solution was found to be around 6.49 to 7.40 for all the formulations. The pH of all formulations is in acceptable range. So they can be easily used in eyes for proper treatment.

Table 4: Result for pH, Clarity Test, Gelling capacity, Gelation temperature

S.NO.	Formulation code	Clarity	pН	Gelling capacity	Gelation temperature	Viscosity 50 rpm)	(at
1.	F1	Transparent	7.23 ± 0.15	+++	26 ± 0.59	78	
2.	F2	Transparent	7.40 ± 0.132	++	27.5 ± 0.7	54	
3.	F3	Transparent	7.39 ± 0.176	-	32 ± 0.12	43	
4.	F4	Transparent	6.49 ± 062	++	29.5 ± 0.31	76	

Table 5: Gelling Capacity

S. No	Gelling Capacity	Observation
1	No gelation	-
2	Gelation occurred in few minutes and remained for few hour	+
3	Gelation immediate, remained for few hour	++
4	Gelation immediate, and for extended period	+++
5	Very stiff gel	++++

Gelling capacity

The gelling capacity of batches was found to be in the range of immediate gelation for extended period to gelation for few hours.

Gelation temperature

The gelation temperature of formulations was found to be in the range 26 to 32.

In-vitro release studies:

Table 6: In-vitro release studies

Time (hrs)	Cumulative % drug release				
	F1	F2	F3	F4	
0.5	22 ± 0.84	18 ± 0.62	20 ± 0.98	17 ± 0.30	
1	35 ± 0.61	26 ± 0.30	28 ± 0.58	24 ± 0.28	
2	46 ± 0.89	37 ± 0.64	38 ± 0.97	33 ± 0.57	
3	52 ± 0.96	45 ± 0.94	47 ± 0.87	42 ± 0.53	
4	70 ± 0.96	56 ± 0.88	59 ± 0.92	54 ± 0.26	
5	83 ± 0.98	60 ± 0.93	63 ± 0.45	59 ± 0.95	




Fig 3: In vitro release of drug Ofloxacin

Summary:

The real challenge in the development of a controlled drug delivery system is not just to sustain the release but also to prolong the presence of the dosage form in the eye until all the drug is completely released in the desired period of time. Various approaches for preparation of in situ ophthalmic gels were designed.

The aim of the present investigation was to formulate and study ophthalmic in – situ gel of ofloxacin. Carbopol, Hydroxy Propyl methyl cellulose (HPMC), Chitosan, and Sodium alginate — were used as polymers for the preparation of ophthalmic in-situ gel. All prepared formulations were evaluated for viscosity, determination of pH, clarity test, gelling capacity, measurement of gelation temperature, and invitro release studies etc.

FTIR spectra of the selected formulations were taken and compared with the spectrum of pure drug. The characteristic peaks of drug were obtained by scanning in the range of 400-4000 cm-1 by using the spectrometer (Bruker- α -T, Germany). It was found that no incompatibility between drug and excipients was obtained.

Solubility is the property of a solid, liquid or gaseous chemical substance called solute to dissolve in a solid liquid or gaseous solvent. The drug was freely soluble in phosphate buffer pH 7.2.

The melting point was determined by the capillary method using melting point apparatus. The melting point of drug was found to be in the range 250°C to 257°C.

The viscosity of gel was determined by Brookfield viscometer. It was obtained in the range 50 to 72cps.

The pH of the in situ gel was found to be in the neutral range 7.2 to 7.82. The pH range of gel shows that any of the formulation can be used easily because it will not produce any irritation in eyes.

The formulations (F1–F4) were prepared by using various concentrations of sodium alginate along with HPMC in different ratios. All the formulations prepared were clear without any turbidity and suspended particles or impurities.

In in-vitro gelation study the formulations were evaluated for their in-vitro gelling capacity, accurately measured 10 mL of formulation was added to 100 mL of 0.1N (HCl, pH 7.2-7.8) at 37°C in a beaker with mild agitation that avoids breaking of formed gel. The in vitro gelling capacity was graded in three categories on the basis of stiffness of formed gel, gelation time and time period for which the formed gel remains as such.(+) Gels after few minutes, dispersed rapidly, (++) Gelation immediate remains for few hours, (+++) Gelation immediate remains for an extended period

Conclusion:

The aim the present study is to develop Ofloxacin *in-situ* gel for sustained ophthalmic preparation. Ofloxacin is an antibiotic that is used to treat bacterial infections; it stops the multiplication of bacteria by inhibiting the reproduction and repair of their genetic material (DNA). Marketed eye drop solution cleared very rapidly from the corneal region whereas, both in-situ gelling systems were cleared at a slow rate and retained at the corneal surface for a longer duration Ofloxacin can be targeted in treatment of the bacterial infection and also reduce dosing frequency, increase bioavailability of Ofloxacin that will result in better patient compliance with minimum side effects.

REFERENCES:

- 1. Baranowski P, Karolewicz B, Gajda M and Pluta J. Ophthalmic Drug Dosage Forms: Characterization and Research Methods. Hindawi publishing corporation scientific world journal, 2014; 861904, 14.
- 2. Madgulkar A, Bhalekar M, Savali S. Formulation, Optimization, and Evaluation of Metronidazole in Situ Gel for Local Treatment of Periodontitis. Human Journals Research Article, 2018; Vol.:12, Issue: 3
- 3. Rao M, Shelar S. Controlled Release Ion Sensitive Floating Oral in situ Gel of a Prokinetic Drug using Gellan Gum. Indian Journal of Pharmaceutical Education and Research, 2015; Vol. 49, 158-167.
- 4. Chauhan P, Dev1 A, Desai1 S, Andhale V. Formulation and Evaluation of Oral In Situ Gel of Metronidazole. American Journal of PharmTech Research, 2016; 6(3), 574-589.
- 5. Saini R, Saini S, Singh G, Banerjee A. In Situ Gels- A New Trends In Ophthalmic Drug Delivery System. International Journal of Pharma Sciences and Research, 2015; Vol. 6 No 05,886-890.
- 6. Remya P. N., Damodharan N. and Anjaneyulu V. Oral sustained delivery of Ranitidine from in-situ gelling sodium-alginate formulation. J. Chem. Pharm. Res., 2011; 3(3),814-821
- 7. Patil S, Kadam A, Bandger S and Patil S. Formulation And Evaluation of an In situ gel for ocular drug delivery of ant conjunctive drug .Cellulose Chem. Techno, 2015;49 (1), 35-40
- 8. Madan JR, Adokar BR, Dua K. Development and Evaluation Of In Situ Gel Of Pregabalin. International Journal of Pharmaceutical Investigation, 2015; Vol. 5 (4), 226-233.
- 9. Ghulaxe C, Kar Pillai M, and Pillai S. Research and Reviews: Journal of Pharmaceutics and Nanotechnology. Rripnt, 2014; Vol. 2 (3), 17-22.
- 10. Morrow GL, Abbott RL. Conjunctivitis. As FAM Physician 1998; 57:735-746.
- 11. Sheikh A, Hurwitz B, Cave J. Antibiotics for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000; 2: CD001211.
- 12. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3 percent ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthamol 1991; 112: 298-338.